Medicxi Growth I LP's Form 4 filing
Centessa Pharmaceuticals plc (CNTA) · filed Jun 24, 2026
- Accession no.
- 0001193125-26-281115
- Filed
- Jun 24, 2026, 4:26 PM ET
- Trade date
- Jun 24, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Medicxi Growth I LPCIK 0001690310 | 10% Owner |
| Medicxi Growth Co-Invest I LPCIK 0001715578 | 10% Owner |
| Medicxi Ventures Management (Jersey) LtdCIK 0001715579 | 10% Owner |
| Medicxi Growth I GP LtdCIK 0001715600 | 10% Owner |
| Medicxi Ventures I GP LtdCIK 0001760411 | 10% Owner |
| Medicxi Ventures I LPCIK 0001760412 | 10% Owner |
| Medicxi Co-Invest I LPCIK 0001760413 | 10% Owner |
| Medicxi Secondary I LPCIK 0001824997 | 10% Owner |
| Medicxi Secondary I GP Ltd.CIK 0001865487 | 10% Owner |
| Medicxi Secondary Co-Invest I LPCIK 0001865493 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 24, 2026 | Ordinary Shares | SSaleDisposed | −4,398,519 | –F3,F4 | – | 0 | Indirect | |
| Jun 24, 2026 | Ordinary Shares | SSaleDisposed | −55,677 | –F3,F4 | – | 0 | Indirect | |
| Jun 24, 2026 | Ordinary Shares | SSaleDisposed | −3,936,970 | –F3,F4 | – | 0 | Indirect | |
| Jun 24, 2026 | Ordinary Shares | SSaleDisposed | −93,526 | –F3,F4 | – | 0 | Indirect | |
| Jun 24, 2026 | Ordinary Shares | SSaleDisposed | −11,197,303 | –F3,F4 | – | 0 | Indirect | |
| Jun 24, 2026 | Ordinary Shares | SSaleDisposed | −281,162 | –F3,F4 | – | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
At the effective time of the Scheme of Arrangement (the "Effective Time"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the "Cash Consideration"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a "CVR") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS.
Referenced by the price of 6 transactions in Table I.
- F4
(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Persons.
Referenced by the price of 6 transactions in Table I.
Remarks
Medicxi Ventures (UK) LLP and Medicxi Ventures (Jersey) Limited act as sub-advisers to Index Ventures Life VI (Jersey) Limited, which acts as the adviser to Index Ventures Life VI (Jersey) LP, and as such, Index Ventures Life VI and Yucca (Jersey) SLP, each of which held Ordinary Shares prior to the transactions reported herein, and the Medicxi Funds may be deemed to be members of a "group" as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended.